Dr. Spear is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
PO box 1108
Rancho Santa Fe, CA 92067Phone+1 858-352-8557
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 1994 - 1997
University of HawaiiInternship, Transitional Year, 1993 - 1994
Stanford University School of MedicineClass of 1993
Certifications & Licensure
CA State Medical License 1998 - 2025
NC State Medical License 2011 - 2012
Clinical Trials
- Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2006 Apr 01
- Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2008 Feb 01
- A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Start of enrollment: 2016 Sep 22
- Join now to see all
Publications & Presentations
PubMed
- 111 citationsPhase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung can...Michael Millward, Timothy J. Price, Amanda R. Townsend, Christopher Sweeney, Andrew Spencer
Investigational New Drugs. 2012-12-01 - 55 citationsPhase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.Michael Millward, P. N. Mainwaring, Alain C. Mita, Kristine C. Federico, G. K. Lloyd
Investigational New Drugs. 2012-06-01 - 27 citationsVascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the ClinicMatthew A. Spear, Patricia LoRusso, Alain C. Mita, Monica M. Mita
Current Drug Targets. 2011-11-30
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
